
## Fredrik Jonsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4913616/publications.pdf Version: 2024-02-01



FREDRIK LONSSON

#	Article	IF	CITATIONS
1	A Bayesian Analysis of the Influence of CSTT1 Polymorphism on the Cancer Risk Estimate for Dichloromethane. Toxicology and Applied Pharmacology, 2001, 174, 99-112.	2.8	55
2	Physiologically Based Modeling of the Inhalation Kinetics of Styrene in Humans Using a Bayesian Population Approach. Toxicology and Applied Pharmacology, 2002, 179, 35-49.	2.8	44
3	Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology, 2001, 157, 177-193.	4.2	43
4	Morphine-3-Glucuronide Has a Minor Effect on Morphine Antinociception. Pharmacodynamic Modeling. Journal of Pharmaceutical Sciences, 1998, 87, 813-820.	3.3	32
5	The Bayesian population approach to physiological toxicokinetic–toxicodynamic models—an example using the MCSim software. Toxicology Letters, 2003, 138, 143-150.	0.8	30
6	Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Archives of Toxicology, 2001, 75, 189-199.	4.2	29
7	A Compartmental Model for the Kinetics of Mercury Vapor in Humans. Toxicology and Applied Pharmacology, 1999, 155, 161-168.	2.8	26
8	Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. Clinical Pharmacokinetics, 2021, 60, 931-941.	3.5	15
9	Development of new technique for risk assessment using physiologically based toxicokinetic models. , 1999, 36, 101-103.		14
10	The Application of a Bayesian Approach to the Analysis of a Complex, Mechanistically Based Model. Journal of Biopharmaceutical Statistics, 2007, 17, 65-92.	0.8	13
11	Bayesian population analysis of a washin–washout physiologically based pharmacokinetic model for acetone. Toxicology and Applied Pharmacology, 2009, 240, 423-432.	2.8	12
12	A pharmacokinetic–pharmacodynamic model for cardiovascular safety assessment of R1551. Journal of Pharmacological and Toxicological Methods, 2011, 63, 123-133.	0.7	9
13	Adjustment factors for toluene, styrene and methyl chloride by population modeling of toxicokinetic variability. Regulatory Toxicology and Pharmacology, 2014, 69, 78-90.	2.7	8
14	A Longitudinal Model for Non-Monotonic Clinical Assessment Scale Data. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 795-815.	1.8	7
15	Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales. AAPS Journal, 2010, 12, 683-691.	4.4	3